Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > EDEN Study
View:
Post by money4golf on Oct 12, 2024 4:03pm

EDEN Study

When will all share holders get this information.

  • Completion of EDEN Observational Study
    • The Company completed its EDEN study in the fourth quarter with 92 patients enrolled. The ancillary observational study collected data on patients with sepsis even if ineligible for Tigris, and captured much needed data on the full range of septic shock and its relation to organ failure and endotoxin activity. These data will inform subsequent discussions with the FDA on labelling for PMX, as well as to provide the medical community and the Company a better picture of the addressable population in the U.S. for PMX. The Company expects final analysis of the data in mid-2024.
  • Remember when this was always included in the press releases!
    • Crude mortality results at both 28-day (primary endpoint) and at one year, thus far, continue to exceed efficacy targets.
  •  
Comment by mercedesman on Oct 13, 2024 8:56am
Agree money4golf ! As it is, Shareholders hear/see very little in the way of promotion, enthusiasm, etc. from Mgt.  Eden and Tigris results, good or bad, should be, at the very least, continually summarized & characterized for all, if known to some.  The fact that Tigris was tracking/ mirroring Euphas 2 results is an important example of good, necessary and fair disclosure ...more  
Comment by mercedesman on Oct 13, 2024 9:20am
Below are the Euphas 2 results referenced in my previous post.  Well worth a read-read  IMO .  https://stockhouse.com/news/press-releases/2023/04/18/spectral-medical-announces-positive-results-of-euphas-2-clinical-trial   I have heard or seen no retraction or correction to previously quantified improvements comparisons (Euphas2, Euphrates, and Tigris)  or ...more  
Comment by BlueJays9293 on Oct 14, 2024 8:12pm
I do love going back over those signals, but today, I just wonder what an eight or a nine in October will do for the share price.  We've all been on a very long and strange road trip, but the true joy of reaching our final destination, can only be fully appreciated, by looking straight ahead thru the front windshield, at those last little bends and curves in the rural highway, until we ...more  
Comment by mercedesman on Oct 14, 2024 9:54pm
Cheers to a hot spring ! ( that we may experience this winter)  MM 
Comment by Spamme54321 on Oct 17, 2024 10:52am
SP rising in very low volume. Spectral better not disappoint with their patient numbers again this month.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities